Premium
Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic‐assisted radical cystectomy
Author(s) -
Kauffman Eric C.,
Ng Casey K.,
Lee Ming Ming,
Otto Brandon J.,
Wang Gerald J.,
Scherr Douglas S.
Publication year - 2011
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09577.x
Subject(s) - medicine , cystectomy , stage (stratigraphy) , bladder cancer , lymphovascular invasion , lymphadenectomy , perineural invasion , urology , surgery , multivariate analysis , cancer , metastasis , paleontology , biology
Study Type – Therapy (case series) Level of Evidence 4 OBJECTIVE• To determine oncological outcomes including early survival rates among unselected bladder urothelial carcinoma (BUC) patients treated with robotic‐assisted radical cystectomy (RRC).PATIENTS AND METHODS• Clinicopathologic and survival data were prospectively gathered for 85 consecutive BUC patients treated with RRC. • The decision to undergo a robotic rather than open approach was made without regard to tumor volume or surgical candidacy. • Kaplan–Meier survival rates were determined and stratified by tumor stage and LN positivity, and multivariate analysis was performed to identify independent predictors of survival.RESULTS• Patients were relatively old (25% >80 years; median 73.5 years), with frequent comorbidities (46% with ASA class ≥3). Of these patients 28% had undergone previous pelvic radiation or pelvic surgery, and 20% had received neoadjuvant chemotherapy. • Extended pelvic lymphadenectomy was performed in 98% of patients, with on average 19.1 LN retrieved. • On final pathology, extravesical disease was common (36.5%). • Positive surgicalmargins were detected in five (6%) patients, all of whom had extravesical tumors with perineural and/or lymphovascular invasion, and most of whom were >80 years old. • At a mean postoperative interval of 18 months, 20 (24%) patients had developed recurrent disease, but only three (4%) patients had recurrence locally. Disease‐free, cancer‐specific and overall survival rates at 2 years were 74%, 85% and 79%, respectively. Patients with low‐stage/LN(−) cancers had significantly better survival than extravesical/LN(−) or any‐stage/LN(+) patients, with stage being the most important predictor on multivariate analysis.CONCLUSION• RRC can achieve adequately high LN yields with a low positive margin rate among unselected BUC patients. • Early survival outcomes are similar to those reported in contemporary open series, with an encouragingly low incidence of local recurrence, however long‐term follow‐up and head‐to‐head comparison with the open approach are still needed.